<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084315</url>
  </required_header>
  <id_info>
    <org_study_id>2015NTLS139</org_study_id>
    <nct_id>NCT03084315</nct_id>
  </id_info>
  <brief_title>Changes in Biomarkers Associated With Use of Electronic Cigarettes</brief_title>
  <official_title>Changes in Biomarkers Associated With Use of Electronic Cigarettes Among African American Menthol and Nonmenthol Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial was to compare the effects of e-cigarettes with and&#xD;
      without nicotine on patterns of combustible cigarette use and biomarkers of exposure to&#xD;
      tobacco toxicants among African American smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares patterns of e-cigarette use and the exposure to the tobacco-specific&#xD;
      carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in African American smokers,&#xD;
      randomized to ad lib e-cigarettes containing nicotine vs. no nicotine. We hypothesized that&#xD;
      nicotine e-cigarettes would be used more than no-nicotine e-cigarettes, and that this would&#xD;
      be associated with reduced use of combustible cigarettes. We hypothesized that nicotine&#xD;
      e-cigarettes would result in more substitution for combusted cigarettes than no-nicotine&#xD;
      e-cigarettes and result in lower levels of exposure to the tobacco-specific carcinogen NNAL.&#xD;
      These results would be relevant for developing exposure reduction strategies for adult&#xD;
      African American smokers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">March 8, 2019</completion_date>
  <primary_completion_date type="Actual">March 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Blocked randomization, block size unknown to staff or investigators</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>All participants are blinded to intervention group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Biomarker Concentrations: Nicotine Equivalents</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Change in concentration of nicotine equivalents in units of mmol/mg creatinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Biomarker Concentrations: NNAL</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Change in urinary concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in units of pmol/mg creatinine.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Average Cigarettes Per Day</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Participants will record the average number of cigarettes smoked per day in the 7 days leading up to each study visit. Outcome is reported as the change in average cigarettes per day from baseline to 6 weeks of treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>E-Cig Zero Nicotine</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>E-Cigarette with no nicotine added</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-Cig 24mg Nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>E-cigarette with 24mg of nicotine added</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>E-Cig Zero Nicotine</intervention_name>
    <description>E-Cig Zero Nicotine</description>
    <arm_group_label>E-Cig Zero Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>E-Cig 24mg Nicotine</intervention_name>
    <description>E-Cig 24mg Nicotine</description>
    <arm_group_label>E-Cig 24mg Nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. self-identify as African American or Black;&#xD;
&#xD;
          2. age 18 years or older;&#xD;
&#xD;
          3. smoke at least five cigarettes daily for the past year;&#xD;
&#xD;
          4. not interested in quitting smoking in the next 6 months;&#xD;
&#xD;
          5. Willing to use e-cigarettes;&#xD;
&#xD;
          6. Good physical health (no unstable medical or mental health condition);&#xD;
&#xD;
          7. no contraindications for e-cigarette use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent unstable or untreated psychiatric diagnosis including substance abuse, as&#xD;
             determined by the DSM-IV criteria;&#xD;
&#xD;
          2. use in the past 30 days of tobacco or nicotine products including e-cigarettes, other&#xD;
             than regular cigarettes;&#xD;
&#xD;
          3. participation in a smoking cessation program in the past 30 days;&#xD;
&#xD;
          4. pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Joseph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DCRU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <results_first_submitted>March 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2020</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>electronic cigarettes</keyword>
  <keyword>nicotine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03084315/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03084315/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>E-Cig Zero Nicotine</title>
          <description>E-Cigarette with no nicotine added&#xD;
E-Cig Zero Nicotine: E-Cig Zero Nicotine</description>
        </group>
        <group group_id="P2">
          <title>E-Cig 24mg Nicotine</title>
          <description>E-cigarette with 24mg of nicotine added&#xD;
E-Cig 24mg Nicotine: E-Cig 24mg Nicotine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 participants in each group withdrew from the study and were not included in the baseline characteristic data.</population>
      <group_list>
        <group group_id="B1">
          <title>E-Cig Zero Nicotine</title>
          <description>E-Cigarette with no nicotine added&#xD;
E-Cig Zero Nicotine: E-Cig Zero Nicotine</description>
        </group>
        <group group_id="B2">
          <title>E-Cig 24mg Nicotine</title>
          <description>E-cigarette with 24mg of nicotine added&#xD;
E-Cig 24mg Nicotine: E-Cig 24mg Nicotine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.74" spread="11.65"/>
                    <measurement group_id="B2" value="50.89" spread="10.74"/>
                    <measurement group_id="B3" value="50.81" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Biomarker Concentrations: Nicotine Equivalents</title>
        <description>Change in concentration of nicotine equivalents in units of mmol/mg creatinine.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E-Cig Zero Nicotine</title>
            <description>E-Cigarette with no nicotine added&#xD;
E-Cig Zero Nicotine: E-Cig Zero Nicotine</description>
          </group>
          <group group_id="O2">
            <title>E-Cig 24mg Nicotine</title>
            <description>E-cigarette with 24mg of nicotine added&#xD;
E-Cig 24mg Nicotine: E-Cig 24mg Nicotine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biomarker Concentrations: Nicotine Equivalents</title>
          <description>Change in concentration of nicotine equivalents in units of mmol/mg creatinine.</description>
          <units>mmol/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="57.23"/>
                    <measurement group_id="O2" value="79.56" spread="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Biomarker Concentrations: NNAL</title>
        <description>Change in urinary concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in units of pmol/mg creatinine.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E-Cig Zero Nicotine</title>
            <description>E-Cigarette with no nicotine added&#xD;
E-Cig Zero Nicotine: E-Cig Zero Nicotine</description>
          </group>
          <group group_id="O2">
            <title>E-Cig 24mg Nicotine</title>
            <description>E-cigarette with 24mg of nicotine added&#xD;
E-Cig 24mg Nicotine: E-Cig 24mg Nicotine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biomarker Concentrations: NNAL</title>
          <description>Change in urinary concentration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in units of pmol/mg creatinine.</description>
          <units>pmol/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="1.74"/>
                    <measurement group_id="O2" value="1.95" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Average Cigarettes Per Day</title>
        <description>Participants will record the average number of cigarettes smoked per day in the 7 days leading up to each study visit. Outcome is reported as the change in average cigarettes per day from baseline to 6 weeks of treatment.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>E-Cig Zero Nicotine</title>
            <description>E-Cigarette with no nicotine added&#xD;
E-Cig Zero Nicotine: E-Cig Zero Nicotine</description>
          </group>
          <group group_id="O2">
            <title>E-Cig 24mg Nicotine</title>
            <description>E-cigarette with 24mg of nicotine added&#xD;
E-Cig 24mg Nicotine: E-Cig 24mg Nicotine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Cigarettes Per Day</title>
          <description>Participants will record the average number of cigarettes smoked per day in the 7 days leading up to each study visit. Outcome is reported as the change in average cigarettes per day from baseline to 6 weeks of treatment.</description>
          <units>cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="6.3"/>
                    <measurement group_id="O2" value="8.6" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>E-Cig Zero Nicotine</title>
          <description>E-Cigarette with no nicotine added&#xD;
E-Cig Zero Nicotine: E-Cig Zero Nicotine</description>
        </group>
        <group group_id="E2">
          <title>E-Cig 24mg Nicotine</title>
          <description>E-cigarette with 24mg of nicotine added&#xD;
E-Cig 24mg Nicotine: E-Cig 24mg Nicotine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Joseph, MD, MPH</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-625-3789</phone>
      <email>lagre010@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

